Earnings Results: Gilead stock rallies as it reports $1.9 billion in sales for its COVID-19 drug in Q4
Shares of Gilead Sciences Inc.’s stock gained 2.1% in after-hours trading on Thursday after the drug maker surprised investors with better-than-expected sales of its COVID-19 drug Veklury during the fourth quarter of 2020.
